Literature DB >> 10927029

Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat.

R Horst1, S Prapong, T Reinhardt, N Koszewski, J Knutson, C Bishop.   

Abstract

The present experiments were conducted to compare the relative hypercalciuric and hypercalcemic activities of 1,24-dihydroxyvitamin D(2) [1,24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1, 24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] in 7-week-old rats. The rats were dosed orally with each sterol for 7 days at a rate of 1 ng/g body weight/day. We also monitored the effect of the three compounds on the induction of mRNA for CaATPase and for 25-hydroxyvitamin D-24-hydroxylase in the kidney and intestine, on plasma vitamin D metabolite levels, and on the capacity to evoke modification in the vitamin D receptor/retinoic acid X receptor (VDR/RXR) heterodimer conformation. Plasma calcium was elevated in the rats treated with 1,24-(OH)(2)D(3) and 1, 25-(OH)(2)D(3), but not in the 1,24-(OH)(2)D(2)-dosed rats. Urinary calcium was elevated significantly (relative to controls) in all groups. The order of hypercalciuric activity was 1,25-(OH)(2)D(3) >/= 1,24-(OH)(2)D(3) >/= 1,24-(OH)(2)D(2) > control. Duodenal plasma membrane calcium ATPase (PMCA) mRNA was elevated to a similar extent in all groups relative to controls. Duodenal 24-hydroxylase mRNA was elevated in all groups relative to controls; however, the elevations were significantly higher in the 1,24-(OH)(2)D(3) and 1, 25-(OH)(2)D(3) groups compared with the 1,24-(OH)(2)D(2) group. Kidney 24-hydroxylase also was elevated significantly in the 1, 24-(OH)(2)D(3)- and 1,25-(OH)(2)D(3)-treated rats but not in the 1, 24-(OH)(2)D(2)-treated rats. Recombinant human vitamin D receptor (hVDR) extracts were incubated with saturating concentrations of 1, 24-(OH)(2)D(2), 1,24-(OH)(2)D(3), and 1,25-(OH)(2)D(3) and subsequently analyzed by electrophoretic mobility shift assay (EMSA). Overall binding was comparable for all metabolites; however, the 1, 24-(OH)(2)D(2) complex exhibited distinctly altered mobility relative to 1,24-(OH)(2)D(3) and 1,25-(OH)(2)D(3), suggestive of an effect on hVDR/hRXR conformation. These data suggest that 1, 24-(OH)(2)D(2) is not as potent as either of the vitamin D(3) sterols at affecting hypercalcemia or hypercalciuria in young growing rats; however, 1,24-(OH)(2)D(2) can evoke other biological responses similar to the vitamin D(3) sterols. These different responses may be related to the alterations in conformation state of the hVDR/hRXR heterodimer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927029     DOI: 10.1016/s0006-2952(00)00378-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Vitamin D Metabolism and Guidelines for Vitamin D Supplementation.

Authors:  Indra Ramasamy
Journal:  Clin Biochem Rev       Date:  2020-12

Review 2.  New Vitamin D analogues for osteodystrophy in chronic kidney disease.

Authors:  John Cunningham
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

3.  Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer.

Authors:  Artur Anisiewicz; Agata Pawlik; Beata Filip-Psurska; Eliza Turlej; Stanisław Dzimira; Magdalena Milczarek; Katarzyna Gdesz; Diana Papiernik; Joanna Jarosz; Dagmara Kłopotowska; Andrzej Kutner; Andrzej Mazur; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2017-11-02       Impact factor: 5.650

4.  Inverse association of vitamin D3 levels with lung cancer mediated by genetic variation.

Authors:  Majda Haznadar; Kristopher W Krausz; Ezra Margono; Christopher M Diehl; Elise D Bowman; Soumen Kanti Manna; Ana I Robles; Bríd M Ryan; Frank J Gonzalez; Curtis C Harris
Journal:  Cancer Med       Date:  2018-05-03       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.